Chul Kim, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Contracted Research
    Ineligible company:
    AstraZeneca, Novartis, Regeneron, Janssen, Genentech, Lyell, Daiichi Sankyo, Gilead, Macrogenics, Boehringer Ingelheim, Black Diamond Therapeutics
    Date added:
    09/11/2024
    Date updated:
    09/11/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Arcus, AstraZeneca, Daiichi Sankyo, Eisai, Regeneron, Sanofi, Takeda, J&J, Pinetree, Boehringer Ingelheim, Gencurix
    Date added:
    09/11/2024
    Date updated:
    09/11/2024
Return to Sept. 27-28, 2024 - Symposium for Evolving Therapies and Drug Development in Oncology